Background: Molecular profiling is becoming increasingly relevant in the management of
patients with advanced cancer; to identify targetable aberrations and prognostic markers to …

Purpose In biliary tract cancer (BTC), standard chemotherapy has limited benefit and no
molecular targeted agents have been approved. This study investigated the genetic profile …

Purpose: Treatment options for advanced cholangiocarcinoma are limited and prognosis is
poor. Cholangiocarcinomas are highly heterogeneous at the molecular level, with divergent …

Biliary tract cancers have dismal prognoses even when cytotoxic chemotherapy is
administered. There is an unmet need to develop precision treatment approaches using …

Opinion statement Biliary tract cancers are relatively uncommon, have an aggressive
disease course and a dismal clinical outcome. Until recently, there have been very few …

Background Advanced cholangiocarcinoma has a poor prognosis. Molecular targeted
approaches have been proposed for patients after progression under first-line …

Cholangiocarcinoma (CCA) encompasses diverse epithelial tumors historically associated
with poor outcomes due to an aggressive disease course, late diagnosis, and limited benefit …

Highlights•CCAs may harbor a range of genetic alterations, some of which are actionable
targets.•It is now recommented to treat patients with IDH1 and FGFR2 alterations with …

Purpose: Various genetic driver aberrations have been identified among distinct anatomic
and clinical subtypes of intrahepatic and extrahepatic cholangiocarcinoma, and these …

Background Targeted therapies have transformed clinical management of advanced biliary
tract cancer (BTC). Cell-free DNA (cfDNA) analysis is an attractive approach for cancer …